PR Newswire Asia's news > Biotechnology

 < Previous page   |   Title only   |   Print    Next page > 
     
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics
Real-time analytics that empower clinical decision-making and pandemic preparedness Global unveiling at ADLM 2025 in Chicago to initiate business partnerships Powered by AI and syndromic ...
2025-07-01T    Biotechnology   Computer/Electronics   Health Care/Hospital   Infectious Disease Control 
Metabolon's Untargeted Metabolomics Services Used for Breakthrough Study Revealing Powerful Link Between Gut Microbiome, the Metabolome, and Type 2 Diabetes (T2D)
Combining metabolomics, gut microbiome, and clinical data may help prevent and personalize the treatment of type 2 diabetes ...
2025-07-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing
SHANGHAI and SINGAPORE , July 1, 2025 /PRNewswire/ -- On June 30 , WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing ...
2025-07-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
TAIPEI and SHANGHAI and SAN FRANCISCO , July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology ...
2025-07-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program
TOKYO , June 30, 2025 /PRNewswire/ -- AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapies for ...
2025-06-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Noul Publishes Its Fifth Sustainability Report, Outlining a Vision for Growth and a Decade of Breakthroughs
"The next decade will focus on securing strong growth momentum by strengthening product competitiveness and profitability" First technology-special listed company to join the Corporate Value-Up ...
2025-06-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
Interim analysis planned for January 2026 with final trial results in late 2026 ...
2025-06-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals
TOKYO , June 30, 2025 /PRNewswire/ -- Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc.  ("Curadh") announced plans to enter a strategic partnership, including ...
2025-06-30T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL
The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces viscosity by up to 90% while maintaining formulation stability ...
2025-06-30T    Banking/Financial Service   Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
NEW YORK , June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO ) today announced that it is moving forward with manufacturing and process development work in preparation for clinical ...
2025-06-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.